{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:01Z","timestamp":1789450081646,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.vaccine.2010.06.083","type":"journal-article","created":{"date-parts":[[2010,7,8]],"date-time":"2010-07-08T08:28:09Z","timestamp":1278577689000},"page":"6086-6093","source":"Crossref","is-referenced-by-count":183,"title":["Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Han-Qing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Hoiseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duzhang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiwen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"DaSilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Pride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubomira","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashoni","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Zlotnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.06.083_bib1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.med.55.091902.103612","article-title":"Opportunities for control of meningococcal disease in the United States","volume":"55","author":"Raghunathan","year":"2004","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"4403","key":"10.1016\/j.vaccine.2010.06.083_bib3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.451601","article-title":"Host defense against N. meningitidis requires a complement-dependent bactericidal activity","volume":"205","author":"Nicholson","year":"1979","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00415494","article-title":"Human bactericidal antibody response to meningococcal outer membrane protein vaccines","volume":"53","author":"Zollinger","year":"1987","journal-title":"Antonie Van Leeuwenhoek"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib5","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1086\/314753","article-title":"Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory","volume":"179","author":"Richmond","year":"1999","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.083_bib6","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"7385","key":"10.1016\/j.vaccine.2010.06.083_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.083_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine vs quadrivalent polysaccharide vaccine in two to ten-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.083_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib10","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992\u20131996","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2010.06.083_bib11","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1016\/S0264-410X(01)00205-5","article-title":"Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6\u20138 October 2000","volume":"19","author":"Cartwright","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.083_bib12","unstructured":"European Union Invasive Bacterial Infections Surveillance (EU-IBIS). Proportion of culture-confirmed N. meningitidis cases in reporting countries by serogroup. Health Protection Agency. London; 2006. http:\/\/www.euibis.org."},{"key":"10.1016\/j.vaccine.2010.06.083_bib13","unstructured":"Centers for Disease Control (CDC). Active Bacterial Core Surveillance Report, Emerging Infections Program Network, N. meningitidis, 2001\u20132006. http:\/\/www.cdc.gov\/ncidod\/dbmd\/abcs\/publications-neis.htm."},{"issue":"12","key":"10.1016\/j.vaccine.2010.06.083_bib14","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci crossreacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/infdis\/171.6.1481","article-title":"Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopepetides","volume":"171","author":"Hayrinen","year":"1995","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2010.06.083_bib16","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the N. meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2010.06.083_bib17","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.vaccine.2005.01.056","article-title":"Outer membrane protein (OMP) based vaccine for N. meningitidis serogroup B","volume":"23","author":"Pillai","year":"2005","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2010.06.083_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA 1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.vaccine.2010.06.083_bib19","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to N. meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.083_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA 1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.083_bib21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to N. meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.083_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of vaccine candidate LP2086 in epidemiologically relevant strains of serogroup B N. meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infec Dis"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2010.06.083_bib23","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1016\/j.vaccine.2009.01.075","article-title":"Detection of LP2086 on the cell surface of N. meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide","volume":"27","author":"McNeil","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.06.083_bib24","series-title":"16th International Pathogenic Neisseria Conference","article-title":"A randomized, placebo-controlled, double-blind, phase I trial of ascending doses of meningococcal group B rLP2086 vaccine in healthy adults [Abstract P213]","author":"Marshall","year":"2008"},{"key":"10.1016\/j.vaccine.2010.06.083_bib25","series-title":"16th International Pathogenic Neisseria Conference","article-title":"Functional cross-reactive antibodies are elicited by a Group B N. meningitidis Bivalent Recombinant Lipidated LP2086 vaccine in Cynomolgus macaques [P100]","author":"Anderson","year":"2008"},{"issue":"10","key":"10.1016\/j.vaccine.2010.06.083_bib26","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1086\/514821","article-title":"Prevalence of factor H binding protein variants and NadA among meningococcal group B isolates from the United States: implications for development of a multicomponent group B vaccine","volume":"195","author":"Beernink","year":"2007","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2010.06.083_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2010.06.083_bib28","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1074\/jbc.M808831200","article-title":"Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086","volume":"284","author":"Mascioni","year":"2009","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.083_bib29","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1128\/IAI.59.9.2963-2971.1991","article-title":"Topology of outer membrane porins in pathogenic Neisseria spp.","volume":"59","author":"van der Ley","year":"1991","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2010.06.083_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2958.2000.02000.x","article-title":"Repeat-associated phase-variable genes in the complete genome sequence of N. meningitidis strain MC58","volume":"37","author":"Saunders","year":"2000","journal-title":"Mol Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.06.083_bib31","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/JB.01308-09","article-title":"Expression of factor H binding protein of meningococcus responds to oxygen-limitation through a dedicated FNR-regulated promoter","volume":"192","author":"Oriente","year":"2010","journal-title":"J Bacteriol"},{"issue":"9","key":"10.1016\/j.vaccine.2010.06.083_bib32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10009242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10009242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:11:35Z","timestamp":1685664695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10009242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":32,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0264410X10009242"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.06.083","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}